New data from the UN health agency highlighted how years of global progress in tackling the preventable disease had been “reversed” since the pandemic overwhelmed health care systems in 2020, preventing vulnerable people from seeking help.
Lockdowns had also stymied many people’s access to essential health care services, WHO’s 2021 Global TB report insisted, before issuing the additional warning that the death toll from the disease “could be much higher in 2021 and 2022”, according to latest projections.
“This report confirms our fears that the disruption of essential health services due to the pandemic could start to unravel years of progress against tuberculosis,” said WHO Director-General, Tedros Adhanom Ghebreyesus. “This is alarming news that must serve as a global wake-up call to the urgent need for investments and innovation to close the gaps in diagnosis, treatment and care for the millions of people affected.”
1.5 million victims
Covering the response to the epidemic in 197 countries and areas, the TB report found that in 2020, some 1.5 million people died from TB in 2020 – more than in 2019.
This included 214,000 patients with HIV, the UN agency said, noting that the overall TB increase was mainly in 30 countries which include Angola, Indonesia, Pakistan, the Philippines and Zambia.
Because of the new coronavirus pandemic, “challenges” which made it impossible to provide and access essential TB services left many people undiagnosed in 2020.
In a worrying development, WHO noted that the number of people newly diagnosed people with the disease fell from 7.1 million in 2019 to 5.8 million in 2020, meaning that far fewer people were diagnosed, treated or provided with TB preventive treatment compared with 2019.
Overall spending on essential TB services also fell, WHO said, adding that the highest drop in TB notifications between 2019 and 2020 were India (down 41 per cent), Indonesia (14 per cent), the Philippines (12 per cent) and China (8 per cent).
“These and 12 other countries accounted for 93% of the total global drop in notifications,” said WHO.
There was also a reduction in provision of TB preventative treatment. Some 2.8 million people accessed this in 2020, which was a 21 per cent reduction since 2019. In addition, the number of people treated for drug-resistant TB fell by 15 per cent, from 177,000 in 2019 to 150,000 in 2020, equivalent to only about one in three of those in need.
Today, some 4.1 million people suffer from TB but have not been diagnosed with the disease or their status has not been reported to national authorities. This is up from 2.9 million in 2019.
The report’s recommendations include a call for countries to put in place urgent measures to restore access to essential TB services, a doubling of investment in TB research and innovation and concerted action across the health sector and others to address the social, environmental and economic causes of TB and its consequences.
- Tuberculosis (TB) is the second deadliest infectious killer after COVID-19. It is caused by the bacteria Mycobacterium tuberculosis that most often affect the lungs. It spreads when people who are sick with TB expel bacteria into the air, for example, by coughing.
- Around nine in 10 people who fall sick with TB each year live in 30 countries. Most are adults but men accounted for 56 per cent of cases in 2020, ahead of women (33 per cent) and children (11 per cent). WHO says that many new cases of TB are attributable to undernutrition, HIV infection, alcohol use disorders, smoking and diabetes.
- The 30 countries with the highest TB burden include Angola, Bangladesh, Brazil, Central African Republic, China, Congo, Democratic People’s Republic of Korea, Democratic Republic of Congo, Ethiopia, Gabon, India, Indonesia, Kenya, Lesotho, Liberia, Mongolia, Mozambique, Myanmar, Namibia, Nigeria, Pakistan, Papua New Guinea, Philippines, Sierra Leone, South Africa, Thailand, Uganda, United Republic of Tanzania, Viet Nam and Zambia.
- TB is preventable and curable. About 85 per cent of people who develop TB can be treated with a six-month drug regimen; treatment has the added benefit of curtailing onward transmission of infection.